ChemicalQDevice

ChemicalQDevice

NIH funding application template for a Phase 1 daraxonrasib and LLM-assisted robotic Whipple trial in KRAS-mutated PDAC.

10.5281/zenodo.21317266

NIH funding application for a Phase 1 daraxonrasib and LLM-directed robotic Whipple trial in KRAS-mutated PDAC.

10.5281/zenodo.21232965

IND application for Phase 1 daraxonrasib with LLM-directed robotic Whipple surgery in KRAS G12-mutated PDAC.

10.5281/zenodo.21097442

Study of repository-based LLMs accelerating Phase 1 pancreatic cancer trial documents and regulatory workflows.

10.5281/zenodo.21018646

Guide to repository-based LLMs for scalable oncology trial documents, simulations, and iterative refinement.

10.5281/zenodo.20843290

Phase 2 protocol for multicenter robotic Whipple surgery with perioperative daraxonrasib in KRAS-mutated PDAC.

10.5281/zenodo.20807027

Phase 1 IND/IDE protocol for LLM-directed robotic Whipple surgery with daraxonrasib in KRAS-mutated PDAC.

10.5281/zenodo.20780121

Congressional framework backing H.R. 9510 and verification-before-generation safeguards for physical AI oncology trials.

10.5281/zenodo.20726461

Clinician trust framework for physical AI oncology trials using ten-gate verification, escalation, and human control.

10.5281/zenodo.20710602

Legislative case for H.R. 9510 using verification-before-generation safeguards in physical AI oncology trials.

10.5281/zenodo.20685379

H.R. 9510 bill v5.0 adding financial transparency, user fees, and funding to verified physical AI oncology trials.

10.5281/zenodo.20619762

H.R. 9510 bill v4.0 presenting the full amendment, grayscale diagrams, tables, and submission appendices.

10.5281/zenodo.20576907

H.R. 9510 bill v3.0 visual amendment with verification evidence, figures, tables, and submission deliverables.

10.5281/zenodo.20535429

Draft Verification Before Generation Act requiring VVUQ clearance before physical AI oncology trial code runs.

10.5281/zenodo.20485580

Draft H.R. 9510 requiring VVUQ review of robot-patient interaction code before generation or execution.

10.5281/zenodo.20454870

Simulation of a Unitree H2 surgical humanoid performing a 60-second Whipple with ten-gate VVUQ assurance.

10.5281/zenodo.20421754

LLM pipeline showing VVUQ verification, not code generation, determines trust in physical AI oncology trials.

10.5281/zenodo.20372501

Four-site, 24/7 humanoid swarm simulation for rapid adverse-event response in physical AI oncology trials.

10.5281/zenodo.20303281

Simulation of an eight-arm robot performing a 60-second Whipple with daraxonrasib for pancreatic cancer.

10.5281/zenodo.20196639

Simulation of a 2030 four-arm robot performing 60-second glioblastoma surgery under on-premises LLM control.

10.5281/zenodo.20113157

Proposed U.S. bills prioritizing patient choice, rights, and control in physical AI oncology clinical trials.

10.5281/zenodo.20045457

Four simulations testing agentic AI for faster oncology patient prediction and real-time trial safety monitoring.

10.5281/zenodo.19994945

Autonomous AI-native sponsor platform using 12 agents to manage physical AI oncology trials with human oversight.

10.5281/zenodo.19396256

Draft national platform for standardized, regulated, and coordinated physical AI oncology clinical trials.

10.5281/zenodo.19244918

Documentation package for California's first physical AI oncology trial site, covering laws, codes, and operations.

10.5281/zenodo.19176370

Autonomous simulation following one lung cancer patient through 10 stages of a regulated physical AI oncology trial.

10.5281/zenodo.19119939

Adaptation of 21 CFR Part 312 for end-to-end physical AI oncology trials and investigational drug applications.

10.5281/zenodo.19057628

Adaptation of 21 CFR Part 50 for human subject protections in end-to-end physical AI oncology trials.

10.5281/zenodo.19040707

Adaptation of ICH E6(R3) into guidance for good physical AI clinical practice in oncology trials.

10.5281/zenodo.18973368

National architecture of five MCP servers for secure, standardized robotic oncology trial data and operations.

10.5281/zenodo.18916731

TrialMCP's five open-source servers linking autonomous trial robots with secure, auditable clinical systems.

10.5281/zenodo.18870961

Federated learning platform unifying privacy, regulation, simulation, and collaboration for robotic oncology trials.

10.5281/zenodo.18795507

Unification Standard Level scoring nine robots for simulation, agentic AI, sharing, and multi-site trial readiness.

10.5281/zenodo.18778220

Tournament of 16 proprietary and open-source LLMs generating FAERS analysis code with iterative learning.

10.5281/zenodo.18029100

AI peer review improves glioblastoma trial matching from 67.3% to 94% accuracy and adds regulatory and FastAPI tools.

10.5281/zenodo.17774560

LLM-built, peer-reviewed machine learning pipeline predicts glioblastoma drug synergy with reproducible deliverables.

10.5281/zenodo.17614396

Projected LLM-assisted oncology workflow reduces development timelines and costs while supporting FDA and ICH compliance.

10.5281/zenodo.17451709

VVUQ-tested pancreatic cancer digital twin simulates 10 trial arms to guide Phase II design, safety, and FDA planning.

10.5281/zenodo.17239510

AI-generated QSP pancreatic cancer trial workflow spanning protocol, Python simulation, VVUQ, and adoption playbook.

10.5281/zenodo.17001137

ChatGPT simulates three reproducible 100,000-patient, five-arm pancreatic cancer Phase III trials over 24 months.

10.5281/zenodo.16415815

AI workflow turns literature and meta-analyses into ranked pancreatic cancer digital twin trial proposals.

10.5281/zenodo.15735068

Autonomous AI meta-analysis of 10 years of glioblastoma trials, pooling survival, safety, hazard ratios, and bias.

10.5281/zenodo.15549831

Multi-LLM workflow reviews and visualizes research across 10 topics to advance lung adenocarcinoma treatment.

10.5281/zenodo.15278152

Deep-research and reasoning LLMs generate traceable pharmaceutical cost solutions, forecasts, and diagrams.

10.5281/zenodo.15072843

LLM analysis of 45 studies identifies cost-saving strategies for monoclonal antibodies and cancer clinical trials.

10.5281/zenodo.14968404

LLM analysis of 100 bevacizumab trial papers tests hallucinations and delivers evidence-based clinical decision support.

10.5281/zenodo.14968162

Conversational AI synthesizes 40 cancer papers into mechanisms, knowledge graphs, and updated signaling pathways.

10.1101/2024.12.28.630597

Conversational AI uses literature retrieval and metabolite tables to forecast advances in antibody bioprocessing.

10.26434/chemrxiv-2024-jzbj0

LLMs rapidly analyze antibody bioprocess data and forecast improvements using retrieval, simulations, and reasoning.

10.26434/chemrxiv-2024-3m7m1

LLMs accelerate paclitaxel biosynthesis review and generate research insights, challenges, and recommendations.

10.26434/chemrxiv-2024-pqjd3

Multimodal models chain 13 spectra to identify a complex organic compound and infer stereochemistry.

10.26434/chemrxiv-2024-06gf1

Large multimodal models interpret NMR spectra and molecular formula data to identify quinoline.

10.26434/chemrxiv-2024-qtnkj

Multimodal models use document retrieval to analyze chemistry literature, spectra, and supplementary files.

10.26434/chemrxiv-2024-p91gm

Report abuse